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ABSTRACT
As technology and research evolve it is essential that practitioners in healthcare remain aware
and cognizant of the changes that are going on around them and how these advancements may
aid them in providing the best care to the patients that seek care from them. The largest
breakthrough in the field of genetics has been the complete sequencing of the human genome.
This landmark has paved the way for innumerable insights into every part of how care is
delivered and stands to change the landscape of medicine entirely. Pharmacogenomics testing
exists as a subset of genetic testing, and pertains to the evaluation of individual genetic variants
that may interfere with the normal metabolism of many medications. There are specialty care
settings where this modality of testing is more prevalent, but it is not well represented in primary
care settings, where it stands to provide a wealth of information to primary care providers as they
manage their patients. Literature review was conducted on this subject of interest and it was
found that there was precedent for the implementation of pharmacogenomics testing in the
primary care setting. Through survey of primary care providers, it was determined that there
were deficits in knowledge and perspective barriers that were adequately addressed with an
educational intervention. This intervention was shown to promote both the potential
implementation of pharmacogenomics testing, generate interest in further education on the
subject of pharmacogenomics, and address the identified perspective barriers.
Keywords: Pharmacogenomics, pharmacogenomics cost-effectiveness,
pharmacogenomics in primary care, implementation of pharmacogenomics
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SECTION ONE: INTRODUCTION
The field of pharmacogenomics is a branch of genetics testing that focuses on the way in
which genetic variants affect the different aspects of drug metabolism, which can produce a
continuum of negative effects in individuals that possess these variants who are taking these
medications currently or may take them in the future. While this testing is widely available to be
utilized in clinical practice there is not yet widespread adoption into clinical practice.
Pharmacogenomics testing is a young field of research that has great promise for positively
changing the way in which medicine is practiced in many ways. It holds the possibility of
preventing potentially dangerous or life-threatening medication-related adverse events, promotes
cost-effective care for patients, promotes increased patient agency in the care team, creates
opportunity for deeper insight into effective management strategies for providers to utilize,
promotes preventative versus reactive management of patients, and deepens the overall
understanding of how vitally important the field of genetics is to the next steps of healthcare
overall.
While there is a large precedent and growing volume of knowledge regarding the benefits
of utilizing pharmacogenomics testing in the clinical setting, there are well-studied barriers to the
widespread adoption and implementation of this type of testing. There have been many
advancements in the field of pharmacogenomics to address these various barriers, but the
prevalence of this testing has remained low. There is little evidence on the subject of the effects
of a targeted educational intervention that addresses the most common themes that stand as
barriers to the implementation and adoption of pharmacogenomics in the primary care setting.
The effects of a targeted educational intervention that addresses these barriers needs to be
understood for conclusions to be drawn regarding approaches to these barriers in future research
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and implementation projects. Therefore, a quasi-experimental study was conducted to determine
the effects of a synthesized educational intervention regarding pharmacogenomics on primary
care providers through comparative analysis of differences between pre and post surveys that
evaluate the perspectives and level of understanding in these providers.
Background
There have been approximately 20 genes that have been evaluated to affect a vast amount
of prescription medications to varying levels of degree. This type of testing focuses on the
identification of genetic variation that affects different aspects of drug metabolism, absorption,
distribution, and elimination. There are also genetic variances known to affect
pharmacodynamics, which disturbs the biological pathways and can represent why patients may
have stronger side effects from certain therapies. Initially, the clinical utilization of
pharmacogenomics testing was through the deployment of monogenic testing on a reactive basis
such as the prescription of pharmacogenetically high-risk drugs. This has, however, proved to be
ineffective and costly, especially in light of advancements in sequencing technology that has
allowed for multiple gene variants to be interrogated simultaneously. There are many potential
cases where multiple genetic variants need to be assessed to understand patients’ risk of adverse
outcomes, and because of this the standard has been shifted towards the standardized testing for
many polymorphisms simultaneously to generate the largest amount of actionable data for care
to be correctly guided (Relling & Evans, 2017).
Historically there have been many noted barriers to the translation of research into
clinical practice for pharmacogenomics testing. There is a lack of incentive for clinicians to order
testing for their patients to prevent adverse events, lack of knowledge regarding the use and
interpretation of this testing, lack of clear and definable clinical guidelines that creates actionable
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recommendations for the provider to change therapy, lack of formal education implemented in
educational curriculum, and lack of laboratories that provide this service, which can be
attributed, in part, to the relatively young field of pharmacogenomics testing (Relling & Evans,
2017).
Adherence to prescribed pharmacotherapies is a prevalent problem in any setting, and a
recent study at the Mayo Clinic found that 91% of the 1,010 participants reported that they
would be more likely to use medications as they are prescribed if the medications were chosen
through pharmacogenomics testing (Olson et al., 2017). Clinical validity and utility for
pharmacogenomics testing has also been validated through the positive effects that have been
evaluated through the ability to predict non-efficacious treatments, as well as providing effective
predictions that improve clinical outcomes (Benitez, Jablonski, Allen, & Winner, 2015). These
clinical outcomes include previously mentioned possible improvements in medication adherence
along with reductions in rates of polypharmacy and avoidance of adverse reactions to
medications. The avoidance of adverse drug reactions categorically has the potential for some of
greatest impact on clinical validity and utility in pharmacogenomics testing, which has the
capacity to comprehensively and accurately assess this type of risk in patients who receive this
testing (Phillips, Veenstra, Oren, Lee, & Sadee, 2001).
One of the strongest established barriers regarding the implementation of
pharmacogenomics testing in the clinical setting has been the economic implications of this
testing and the unclear return on investment with this new means of insight (Wong, Carlson,
Thariani, & Veenstra, 2010). Contributing to this issue is the lack of significant insights into the
clinical utility and validity of this new testing tool, which is inevitably complicated by the lack of
widespread implementation, study, and adherence to recommendations that are based on testing
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itself (Berm et al., 2016; Sauver et al., 2016). However, there have been helpful breakthroughs
on this discussion of economic utility in the implementation of pharmacogenomics testing that
stand to address this issue thoroughly. Berm et al. (2016) found through systematic review of 80
previous studies centered around the cost-effectiveness of pharmacogenomics testing that there
was substantial evidence in the majority of evaluated studies that this was not only cost effective
but also promoted better clinical outcomes. This review was based on previous evidence that
supported the cost effectiveness of pharmacogenomics testing, but did find inconclusive data
regarding the clinical utility and validity of testing in some of the evaluated studies (Wong,
Carlson, Thariani, & Veenstra, 2010). In another systematic review it was found that there was
strong evidence for the utilization of pharmacogenomics testing towards the goal of preventing
adverse drug reactions for specific pharmacotherapies (Pumpton, Roberts, Pirmohamed, &
Hughes, 2016). It was established in all of these reviews that a limitation of the results that were
evaluated was the absolute dependence on comprehensive and accurately reported data from
implementation projects on which the outcomes of cost-effectiveness, clinical validity, and
improvement in clinical outcomes was based (Berm et al., 2016; Pumpton, Roberts,
Pirmohamed, & Hughes, 2016; Wong, Carlson, Thariani, & Veenstra, 2010).
These findings are the basis for an educational intervention being targeted towards
addressing the knowledge base as well as the perspectives of providers in the clinical
environment. Sauver et al. (2016) highlighted the complications of poor understanding and false
perspectives regarding pharmacogenomics, with 52% of clinicians not understanding how to
incorporate pharmacogenomics into their future practice along with not expecting this
incorporation to take place at all. Additionally, it was found that 53% of the surveyed clinicians
had very poor responses to the clinical decision tools set in place to alert them of possible
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changes in management, and only 30% of the surveyed clinicians changed their
pharmacotherapy to a different agent based on the recommendations supplied by
pharmacogenomics testing (Sauver et al., 2016). Potential clarification for these findings was
provided through the surveying of healthcare professionals in a different context, which revealed
that while a vast majority of the participants believed that pharmacogenomics was relevant to
their clinical practice, there were very few cases of personal implementation of this testing due to
variables such as interpretation of testing results and knowledge regarding basic principles of
pharmacogenomics (Just et al., 2017).
Due to these factors and variables it has been established that the phenomenon of interest
relating to pharmacogenomics testing include the barriers of poor understanding and negative
perspectives from providers who can provide the testing. There have been initiatives regarding
pharmacogenomics education that have proven to be innovative in their approach and effective at
promoting an enhanced understanding of pharmacogenomics testing (Adams et al., 2016). To
understand the efficacy of pharmacogenomics testing and how to best implement this new
management tool into clinical practice the barriers that exist need to be investigated and
addressed comprehensively.
Problem Statement
There is a vast amount of evidence that exists to support the widespread implementation
of pharmacogenomics testing in regular evaluation and management of patients seeking primary
care, as there are many known and potential benefits through the use of this testing. The barriers
that stand in the way of appropriate translation of research into clinical practice need to be
evaluated thoroughly to appropriately address these variables and implement pharmacogenomics
testing effectively in the primary care setting. There is evidence in the literature regarding the

PHARMACOGENOMICS IN PRIMARY CARE: BARRIERS TO IMPLEMENTATION

13

barriers that exist, but insight needs to be drawn from these findings to create an intervention that
should then be validated and refined through further research and implementation.
Purpose of the Project
The purpose of this project is to evaluate the impact of a targeted educational intervention
on a population of primary care providers’ perspectives and levels of understanding. This will be
accomplished through establishing the barriers that are found in the literature that historically
stand against the implementation of pharmacogenomics testing, and comparing these findings
with the specific barriers that are found within the population of interest by means of surveying.
These survey results will be combined with what is known in the literature to provide a targeted
educational intervention that is comprehensive while being contextual to the specific needs of the
population being studied. The project’s primary objective is to evaluate the efficacy of a targeted
educational intervention at addressing the barriers to implementation of pharmacogenomics
testing in clinical practice.
Clinical Question
How does a targeted educational intervention affect the reported level of understanding
and perspectives for providers in a primary care setting?
SECTION TWO: LITERATURE REVIEW
Search Strategy
Systematic search through the literature for original research regarding the subject of
pharmacogenomics was conducted. The evaluated databases included ProQuest, ScienceDirect,
Public Library of Science, ClinicalKey, SpringerLink, and JAMA Network. The search terms
used to procure evidence included “pharmacogenomics”, “pharmacogenomics cost-
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effectiveness”, “pharmacogenomics in primary care”, “pharmacogenomics in primary care”, and
“implementation of pharmacogenomics”. Filters utilized for the review of relevant material
included articles that were published in the English language within the last 10 years. Articles
older than 10 years were not included due to the lack of relevance to the subject of
pharmacogenomics presently. One article that does not meet the aforementioned filters was
included for deeper background and historical context regarding the subject matter. A total of 37
studies were found and of these 15 were kept for final review. The studies that were kept for
inclusion were those that had relevance to the variables that stand as barriers to the
implementation of pharmacogenomics, which are being assessed in this project. The studies
included in this literature review discuss main points of interest in the themes identified as being
important in the evaluation of pharmacogenomics testing.
The studies included in the literature review contained several systematic reviews, which
contributed to important conclusions regarding the variables of cost-effectiveness of
pharmacogenomics testing in clinical use, as well as the clinical validity and utility of this testing
(Berm et al., 2016; Pumpton et al., 2016; Wong et al., 2010). In addition to the literature
providing insight into the cost-effectiveness of pharmacogenomics testing, there was also a
systematic review that demonstrated the worth of pharmacogenomics testing to provide better
clinical outcomes and prevent adverse drug reactions in patients receiving pharmacotherapies
(Phillips, Veenstra, Oren, Lee, & Sadee, 2001). There was also a single correlational design
study that was included to identify specific and practical findings regarding the cost-savings that
are seen with patients undergoing pharmacogenomics testing (Brown, Lorenz, Li, & Dechario,
2017). There were several articles included that had descriptive designs to provide support for
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the notion of deficient provider knowledge base of pharmacogenomics testing (Relling & Evans,
2015; Rosenman et al., 2017; Sauver et al., 2016).
Critical Appraisal
The overall body of evidence that was found through the review of literature shows
support for the project’s interests and the variables that are to be addressed with the intervention
included. Systematic reviews that were included in the literature review were evaluated using the
CASP (2018) appraisal tool, which revealed that the results were valid and showed strong
support for the results and conclusions that were drawn in these reviews. According to the CASP
appraisal tool, the only point in which the systematic reviews were deficient was the uncertainty
regarding the results being directly applicable to the contextual circumstances of this project’s
focus.
Important conclusions that were found through the review of literature should be
scrutinized for potential bias and inability to generalize results. Examples of this include the
findings of Sauver et al. (2016), which showed that there was a large percentage of surveyed
clinicians who did not find the direct application of pharmacogenomics in their practice and had
only changed practice due to pharmacogenomics results on very few occasions. There may be
variables that are not obvious that can account for these findings, such as poor implementation
plan of pharmacogenomics testing that did not include adequate education regarding the subject
of pharmacogenomics, lack of clinical support in the implementation of this testing, age of the
clinicians, previous experience with pharmacogenomics testing, or lack of clinician input into the
clinical support tools that were utilized as part of this study by Sauver et al. (2016). Rosenman et
al. (2017) found that the implementation of pharmacogenomics testing in their setting required
leveraging key stakeholders in both hospital administration as well as clinicians who were
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experts in this field to educate and assist other clinicians in the use and interpretation of
pharmacogenomics testing. Beyond this, there was also discussion regarding the type of
education that clinicians received, the frequency that this training was reinforced, and the support
systems that were established to promote this change. If these variables were present in the
previously mentioned study, it may have affected dramatic changes on the outcomes that were
listed.
Similarly, the findings of Just et al. (2017) can be negatively affected by bias that was not
reported or controlled for in the study. The characteristics of the surveyed population were not
explained thoroughly, which may have represented several issues of bias or inexperience that
cannot be accounted for otherwise. Berm et al. (2016) explained some conflicting results in the
systematic review of literature on the subject of economic utility of pharmacogenomics testing.
Within the article it was explained that the conflicting results were due to the inadequate
reporting of results in evaluated studies or the ineffective implementation of pharmacogenomics
testing in the clinical setting, which promotes poor provider adherence to recommendations and
subsequent misrepresentation in the data.
Synthesis
Overall, the evidence that was found in the review of literature suggested that there was
significant precedent for the cost-effectiveness for pharmacogenomics testing being implemented
in clinical practice. However, these studies also concluded that further research was needed to
provide conclusive evidence for the recommended scope of implementation with
pharmacogenomics, as well as the extent of the clinical validity and utility that this testing
provides patients (Berm et al., 2016; Pumpton et al., 2016; Wong et al., 2010). One of the
distinct areas of clinical utility and promotion of patient outcomes through pharmacogenomics
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testing in primary care settings was mental health care (Brown, Lorenz, Li, & Dechairo, 2017).
These findings support this project’s goal of addressing this known barrier of pharmacogenomics
implementation in clinical practice.
Conceptual Framework/Model
The conceptual framework that is utilized for the formation of this project is the Iowa
Model of Evidence-Based Practice. The Iowa Model stands as a valuable tool to clinicians who
are seeking to address a clinical problem by providing a framework that can be utilized to answer
essential questions regarding the necessary components of any project. This model serves as the
underpinning that continually shapes and refines the theoretical intervention for this clinical
problem (Iowa Model Collaborative, 2017). In this scholarly project the triggering issue was new
evidence regarding the use of pharmacogenomics testing in general, but more specifically how
this testing can and should be implemented in the setting of primary care. This general concept
was further refined by identifying a subsection of data within the overall scope of
pharmacogenomics that pertains to the identified barriers that stand in opposition to the
implementation of this testing within the primary care setting. The clinical question of primary
care providers’ perspectives and level of knowledge regarding pharmacogenomics testing was
decided upon as the purpose of this scholarly project.
With the utilization of the Iowa Model it was determined that the next step in this process
was to understand if this chosen topic is a priority within the chosen population of primary care
providers. It was determined through further literature review that there was significant
precedence for the importance of this topic both within the primary care setting and to primary
care providers. Once the subject of this scholarly project was determined to have importance, the
Iowa Model was followed again in the next step of synthesizing a body of evidence that was in
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support of the scholarly project’s purpose. This was accomplished with systematic and
comprehensive literature review and the use of literature evaluation tools to understand the
quality of the evidence that was being gathered.
After it was determined that there was sufficient evidence to support the purpose of the
scholarly project, the next step that was taken was to design the intervention that was going to be
delivered to the primary care providers who decided to take part in this project’s work. The Iowa
Model was again followed systematically in the development of the materials that were
developed for the intervention and evaluation of potential practice change. Through these
materials that were developed for this project it was determined that change in practice was
appropriate and that adoption was readily possible. Once these positive results were obtained
regarding the purpose of the scholarly project, there were follow-up opportunities identified
using the project materials to understand how this potential change in practice could be best
supported and nurtured. The results obtained in the course of this scholarly project will be
disseminated by potential publication and encouragement for others to validate these results by
replication studies.
Summary
The literature review for this project revealed key findings regarding the evidence that
exists to support the goals of the project, which is to provide a targeted educational intervention
to primary care providers that will address areas of deficient knowledge as well as correcting
incorrect perspectives of pharmacogenomics testing. The literature on this subject demonstrates
preexisting barriers to successful implementation of pharmacogenomics testing in other settings
such as deficiency in knowledge base, financial concerns, lack of clinical guidelines for
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therapeutic changes, and efficacy of testing in preventing adverse clinical outcomes, as well as
promoting optimal patient care.
SECTION THREE: METHODOLOGY
Design
This project is an evidence-based practice project that is guided by the Iowa Model for
Evidence-Based Practice. The design of this project is quasi-experimental, which will guide the
outcomes of interest in how they pertain to the clinical phenomenon of interest. This project
builds upon the foundation of evidence that has been established in the literature regarding the
use of pharmacogenomics testing as a means of regular management and evaluation in primary
care settings. Specifically, this project sought to gain an understanding of the levels of
knowledge in primary care providers regarding the use of pharmacogenomics testing as well as
their perspectives on this type of testing. It has been noted in other settings that deficient
knowledge base and perceptions of clinical validity, clinical utility, cost-effectiveness, and lack
of clinical guidelines serve as significant barriers to the implementation of pharmacogenomics
testing. These variables were evaluated in the population of chosen primary care providers to
understand if there was variance or consistency with what is represented in the literature. A
chosen group of primary care providers in the state of Virginia were surveyed regarding these
variables of interest. The results were compared against what is represented in the literature and a
targeted educational intervention was curated and delivered to those that provided responses to
the original survey. A post-survey was then administered to determine potential changes in
knowledge base or perceptions, as well as likelihood to include pharmacogenomics testing as a
result of the intervention.
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Measurable Outcomes
Measurable outcomes for this project include positive change in primary care provider
behavior regarding the likelihood of ordering pharmacogenomics testing for patients seeking
care, positive comparative change in knowledge base or understanding of pharmacogenomics
testing and its application in the clinical setting, and positive comparative change in the
perceptions of pharmacogenomics testing.
Setting
This project was not carried out in any one specified organization. The project materials
were distributed to primary care providers that were identified as having the ability to order PGx
testing and act on its results. The project considers nurse practitioners (NP), physician assistants
(PA), and medical doctors (MD) to all meet the criteria of being primary care providers. The
goals of advancing care outcomes for primary care patients through the implementation of PGx
testing was found to be generally recognized as being aligned with the various disciplines of
providers included for this project. The primary care providers were all located within the state
of Virginia and were verified to be in active practice at various primary care practices throughout
the state. Support for the project and its aims were evaluated through voluntary participation in
the project.
Population
As stated in the previous section, the participants that were included in this project were
those that were verified to be primary care providers that were in active practice in the state of
Virginia. Primary care providers were determined to be any provider that had the practice
authority and ability to order PGx testing for their patients. Thus, NPs, PAs, and MDs were all
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included in the project population. The rationale for this chosen population is to identify those
who have the ability to order this testing for their patients within the primary care setting,
identify their individual and collective perspectives on PGx testing, and determine if these
perspectives change with the application of an educational intervention that adequately describes
the basic nature of PGx testing and its applications towards providing better outcomes for
patients. Exclusion criteria for this project consisted of either not meeting the determined
qualifications for being considered a primary care provider or primary care providers that are not
in current practice. The selection process for this project consisted of the primary researcher
identifying potential candidates for inclusion in the project and sending information regarding
this scholarly project via e-mail to the potential participants’ work emails that were obtained via
primary care listings and websites. The project sample is one that is purposive in methodology,
as there were criteria that were required for participation, but this was not randomized in nature.
There were 21 participants included in this project. There are several descriptive features
about this project’s population that will be detailed here. The large majority of the project’s
participants were under the age of 45 with 38.1% reporting to be within the age range of 25-34
years and 38.1% within the age range of 35-44 years. The majority of participants reported to be
MDs (47%), which was followed by PAs (33%) and then NPs (20%). The majority of those
surveyed reported that their level of experience in their current role was 1-10 years (76%). The
participants also reported a slight majority of females (57%) versus males (43%).

Ethical Considerations
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This project is intended to be constructed to protect the privacy and responses of all
chosen subjects. Research ethics training was completed to ensure the protection of privacy and
security of potentially sensitive information obtained from the subjects through the use of survey.
The electronic communications to the individuals selected for participation in this project
included a formal informed consent document, information regarding consent being given by
means of participation, details regarding the use of the data that would be collected, and the
measures that would be taken to keep this information secured and private. University IRB
approval was obtained and it was determined that further organizational IRB approval for each
participant was unnecessary due to the low-risk nature of this project. This was determined
through approval from both the scholarly Chair and university IRB representatives.
Data Collection
The method of data collection for this project was accomplished through electronic
communications from the researcher to the intended individuals who met the criteria set forth for
inclusion regarding their participation in the project. Project participants were contacted directly
by the primary researcher with a request for their participation through completion of project
materials. Each participant was provided information regarding the project, its aims, and URL
links to complete the project materials. Data were then aggregated utilizing a surveying service.
Tools
There have been tools utilized to understand the barriers to implementation of
pharmacogenomics testing, but there are several variables of interest and factors that exist within
the intended context of study that require the development of a new tool to adequately determine
the variables of interest as well as their relationship with the context and the subject of
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pharmacogenomics testing in primary care. The project’s pre survey, educational intervention,
and post survey were all constructed by the primary researcher. Evidence found within the
literature served as the conceptual foundation for the tools that were utilized within the project.
However, many of the tools that were found within the literature specifically dealt with providers
who already had some modest level of exposure to the concepts of PGx testing, which was not
the case within this project. Therefore, all of the identified tools within the literature were not
useful for appropriated implementation within this project.
Intervention
This scholarly project began with the identification of this phenomenon of interest. PGx
testing was initially evaluated in a generalized manner, but was subsequently considered in light
of its potential application within the context of primary care management. This refined
phenomenon of interest was investigated further and it was determined that the lack of PGx
testing within primary care settings is in itself a subject that had been researched by others
previously. With this foundational literature being present, it was determined that this project’s
aim was to progress the study of this phenomenon by development of materials that both
identified primary care providers’ perspectives towards PGx testing and attempted to improve
these perspectives for the purposes of improved implementation of this testing within the
primary care setting.
Once this baseline for the project was established a comprehensive literature review was
accomplished. After the aims, goals, and structure of the project were established, the primary
researcher obtained university IRB approval for carrying out the project in the chosen population
of primary care providers. Potential participants were contacted by the primary researcher via email and were voluntarily enrolled in the project. Once participants had completed all project
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materials the primary researcher gathered and aggregated the responses that the participants had
provided in both the project pre-survey and post-survey. These data were then analyzed through
the use of statistical tools to determine significance and meaningful conclusions were then
drawn.
Timeline. The literature review for this project was concluded on June 7, 2019.
University IRB approval was obtained on September 18, 2019. Implementation of the project
was carried out from November 15, 2019 through March 4, 2020. Data analysis was completed
on April 20, 2020.
Feasibility Analysis. The anticipated feasibility of this project is high. The costs
associated with carrying out this project include the use of proprietary survey tools to distribute
the pre-survey and post-survey, along with included collection methods and data analysis.
Data Analysis
Measurable Outcome 1. The first measurable outcome of interest that was evaluated in
this project was the presence and significance of deficits in knowledge regarding PGx testing as
a barrier for implementation of this testing.
Measurable Outcome 2. The second measurable outcome of interest that was evaluated
in this project was the likelihood of pursuing further education about PGx testing based on
participation, as well as the methods by which this would be best accomplished according to the
surveyed population.
Measurable Outcome 3. The third measurable outcome of interest that was evaluated in
this project was the significance of the educational intervention on changing the perspectives of
primary care providers regarding PGx testing.
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SECTION FOUR: RESULTS
Measurable Outcome 1
This scholarly project utilized survey tools that were original to this project and were
created by the primary researcher. These survey tools were shaped and characterized by evidence
that was found within the literature review; however, there was not a survey tool identified
within that search that adequately addressed the variables that have been established in the
survey tools that were utilized in this scholarly project. There were two surveys developed for
this scholarly project. It was the aim of the pre survey to gather baseline information on the level
of knowledge and experience that the surveyed providers had with pharmacogenomics testing.
Beyond this aim it was also determined that the pre survey should be designed to ascertain if
perspectives were present or absent in the surveyed population, which would also help to
determine how the educational intervention and post-survey were structured in their content and
questioning. The post survey sought to understand changes in the perspectives and level of
knowledge in the surveyed providers in comparison to the results that were evaluated on the pre
survey tool.
The data gathered from the survey results for this project showed that there was a
statistically significant relationship between the current level of knowledge reported by the
participants and main barrier for PGx testing being clinical responsibility associated with this
testing. This relationship is clarified with knowledge that within the project population, 95% of
the participants reported having at most, very little experience with PGx testing. On the pre
survey, where this relationship is being evaluated, the qualification for the response of very little
experience is that providers had just heard PGx mentioned but have no actual training in the
concepts of PGx testing. This is reemphasized with it being noted that 95% of surveyed
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providers stated that they never include PGx testing as part of their management for patients
currently. The hallmark of the descriptive statistics for the pre-survey in this project was that
90% of surveyed providers stated that the unfamiliarity with testing was the main barrier to the
implementation of PGx testing, as well as 90% of surveyed providers also stating that there is no
application for PGx testing in their practice currently. This overwhelming presence of responses
that indicate a deficit in knowledge and overall unfamiliarity leads quite reasonably to 95% of
surveyed providers stating that they are completely uncomfortable interpreting PGx testing
results based on their current level of knowledge.
Beyond these descriptive statistics that outline the first measurable outcome are
inferential statistics that further develop this theme with statistically significant findings that
further reinforce these preliminary findings. A Kruskal-Wallis H test showed that there was a
statistically significant difference in participants who found the main barrier for
pharmacogenomics testing being clinical responsibility between the current knowledge level of
pharmacogenomics, χ2(2) = 4.2, p = 0.04 with a mean rank score of 10.0 for participants that
responded no and 17.0 for participants that responded yes. The Mann-Whitney U Test statistic is
45.0 with a significance value of 0.08, which shows that there is a significant difference between
the two factors. Another Kruskal-Wallis H test showed that there was a statistically significant
difference in participants who found the main barrier for pharmacogenomics testing being
clinical responsibility between the significance of pharmacogenomics testing, χ2(2) = 5.979, p =
0.014 with a mean rank score of 9.75 for participants that responded no and 18.5 for participants
that responded yes. The Mann-Whitney U Test statistic is 49.5 with a significance value of
0.017, which shows that there is a significant difference between the two factors.
Measurable Outcome 2
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The data gathered from surveying this population of primary care providers also outlined
distinctive trends that bore out interesting themes in relation to the second outcome of
measurement that has been established. It was noted in the pre-survey portion that given the
current level of knowledge regarding PGx concepts, only 14% of providers indicated that they
believe it is not very important to include PGx education in medical education curriculum. This
is reflected in the responses given regarding what formats are important for increased knowledge
regarding PGx concepts. To this question only 19% of providers indicated that graduate school,
meaning medical school, PA programs, and NP programs, were important to furthering
education on PGx testing. However, in response to this same question, which allowed for
multiple answers to be selected, 85% of providers indicated that conferences were important to
gain knowledge, while 90% indicated that continuing education courses were important to
increasing understanding of PGx testing. Finally, only 5% of surveyed providers indicated in the
final question of the pre survey that they were not very interested in receiving education on PGx
testing.
Based on the data acquired from the pre-survey there were statistically significant
relationships drawn between variables of interest. A Kruskal-Wallis H test showed that there was
a statistically significant difference in participants who found graduate schools as the best format
for increasing knowledge about pharmacogenomics between the interest regarding
pharmacogenomics testing education, χ2(2) = 7.508, p = 0.006 with a mean rank score of 9.35
for participants that responded no and 18.0 for participants that responded yes. The MannWhitney U Test statistic is 72.0 with a significance value of 0.036, which shows that there is a
significant difference between the two factors. Another Kruskal-Wallis H test showed that there
was a statistically significant difference in participants who found the Internet as the best format
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for increasing knowledge about pharmacogenomics between the importance of
pharmacogenomics education, χ2(2) = 5.007, p = 0.025 with a mean rank score of 9.2 for
participants that responded no and 15.5 for participants that responded yes. The Mann-Whitney
U Test statistic is 82.5 with a significance value of 0.019, which shows that there is a significant
difference between the two factors. A Kendall's tau-b correlation was run to determine the
relationships between importance of pharmacogenomics education and the interest regarding
pharmacogenomics testing education, significance of pharmacogenomics testing, and current
knowledge level of pharmacogenomics amongst the 21 providers. There was a strong, positive
correlation between importance of pharmacogenomic education and the three comparative
factors. Interest regarding pharmacogenomics testing education (τb = 0.436, p = .0.028),
significance of pharmacogenomics testing (τb = 0.536, p = .0.006), and current knowledge level
of pharmacogenomics (τb = 0.601, p = .0.003) were all statistically significant. These results are
detailed in Table 1 with the mentioned correlations and statistical significance denoted.
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It was determined that there was statistically significant evidence in the gathered data
regarding interest in PGx education as well as which formats were most desirable in
accomplishing this furthered knowledge. It was found that 86% of surveyed providers indicated
on the post survey that they were at least somewhat likely to pursue further PGx education as a
result of participation in the project. It was also noted that 71% of the surveyed providers
completely agreed that PGx should be included in the preparatory curriculum of those entering
the medical field or offered as continuing education opportunities for those in the field of
primary care. The remaining 29% of surveyed providers indicated on the same question that they
somewhat agreed with this notion as well. However, the importance of further efforts to educate
primary care providers with more advanced concepts of PGx testing cannot be understated, as
95% of surveyed providers listed insufficient knowledge base as a barrier to implementation of
PGx testing.
Measurable Outcome 3
The third and final outcome measurement is defined by the perspectives that were found
within the surveyed population in the pre-survey and how these perspectives shifted as a result of
the educational intervention that was delivered to them in the course of the project. It was
identified on the pre-survey that providers believed that PGx testing did not have much clinical
significance, with only 10% indicating PGx testing results were somewhat significant to patient
outcomes while 43% indicated that this had very little significance or no significance at all to
patient outcomes. It was also identified that 48% of surveyed providers saw the cost of testing as
a prohibitive factor in the implementation of PGx testing. In response to asking what the main
barrier was to implementation of PGx testing, 24% of providers chose cost of testing, 24% of
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providers chose lack of impact on clinical practice, and 52% chose lack of evidence for clinical
use.
A Kruskal-Wallis H test showed that there was a statistically significant difference in the
main barrier for pharmacogenomics testing being the cost of testing when compared with cost
being prohibitive for testing, χ2(2) = 5.469, p = 0.019 with a mean rank score of 12.56 for
participants that responded no and 6.0 for participants that responded yes. The Mann-Whitney U
Test statistic is 15.0 with a significance value of 0.04, which shows that there is a significant
difference between the two factors. A Kendall's tau-b correlation was run to determine the
relationship between interest regarding pharmacogenomics testing education and the significance
of pharmacogenomics testing and likeliness to pursue pharmacogenomics testing amongst 21
participants. There was a strong, positive correlation between interest regarding
pharmacogenomics testing education and the two factors. Significance of pharmacogenomics
testing (τb = 0.439, p = .0.028), and likeliness to pursue pharmacogenomics testing (τb = 0.592, p
= .0.003) were both statistically significant.
In the post survey data it was clear that there was a distinct change in the answering of
questions regarding the identified perspectives from the pre survey, with 85% of surveyed
providers who at least somewhat agreed that the educational intervention thoroughly addressed
the barriers to implementation of PGx testing. It was also found that at least 90% of the surveyed
providers at least somewhat agreed that PGx testing has clinical significance in the management
of primary care, 80% at least somewhat agreed that PGx testing is financially viable in the
management of primary care patients, and 95% indicating that they at least somewhat agreed that
PGx testing can greatly reduce adverse drug reactions in patients. When asked who PGx should
be considered for in a multiple response style question, 95% of surveyed providers indicated that
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the cases where adverse drug reactions are more likely, and 58% indicated that this should also
be considered for patients where normal therapies are noted to be ineffective.
A Kruskal-Wallis H test showed that there was a statistically significant difference in
participants who planned to pursue pharmacogenomics education due to the project and between
intervention testing considered normal therapy ineffective, χ2(2) = 4.365, p = 0.037 with a mean
rank score of 8.0 for participants that responded no and 13.25 for participants that responded yes.
The Mann-Whitney U Test statistic is 85.0 with a significance value of 0.036, which shows that
there is a significant difference between the two factors. Another Kruskal-Wallis H test showed
that there was a statistically significant difference in participants who found pharmacogenomics
testing significant due to the intervention and between testing considered normal therapies
ineffective due to the intervention, χ2(2) = 5.47, p = 0.019 with a mean rank score of 7.83 for
participants that responded no and 13.38 for participants that responded yes. The Mann-Whitney
U Test statistic is 82.5 with a significance value of 0.019, which shows that there is a significant
difference between the two factors. A Kendall's tau-b correlation was run to determine the
relationship between participants who found pharmacogenomics testing to have significance
because of the intervention and whether pharmacogenomics concepts should be included in
preparatory curriculum of those entering the medical field amongst 21 participants. There was a
strong, positive correlation between participants found the intervention addressed barriers and
whether intervention testing is viable. Whether intervention testing is viable (τb = 0.663, p =
.0.003) was statistically significant. Kendall's tau-b correlation was run to determine the
relationship between participants who, due to the intervention, found that pharmacogenomics
testing can greatly reduce adverse drug reaction events, whether PGx testing is viable,
participants who stated that they are planning to pursue pharmacogenomics education due to the
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project, and if the intervention is appropriate for primary care amongst the 21 providers. There
was a strong, positive correlation between all the three factors. Whether intervention testing is
viable (τb = 0.436, p = .0.037), participants planning to pursue pharmacogenomics education due
to the project (τb = 0.509, p = .0.015), and if the intervention is appropriate for primary care (τb
= 0.529, p = .0.014) were all statistically significant. These results are detailed in Table 2 with
the mentioned correlations and statistical significance denoted.

Table 2: Kendall's Tau-b correlation testing on post-survey results
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SECTION FIVE: DISCUSSION
Implication for Practice
The findings based on the project’s measurable outcomes contribute to the growing
knowledge surrounding PGx overall, but more specifically the method by which this advent of
personalized medicine can and should be implemented in the primary care setting. Previous
research has focused primarily on evaluating the efforts to implement PGx testing, the
generalized themes that stand as general barriers to the implementation of this testing, and
evaluation of the potential benefits of implementing PGx testing in various care settings. In this
project it was established that in the surveyed population of primary care providers there was an
overwhelming baseline deficit in knowledge regarding the most basic concepts of what PGx
testing is, its application, and common misconceptions about the testing itself. Beyond this, it
was determined that through exposure to an educational intervention that included the core
concepts of PGx testing that providers were willing to pursue the inclusion of this testing in their
practice as well as to engage in further education regarding the subject of PGx testing. As a result
of the survey responses, this project was also helpful in illuminating the perceived need for
education about PGx concepts to be included in preparator curriculum and to be offered as
continuing education opportunities for those in the field of primary care.
The importance of these findings for both the surveyed providers as well as the patients
that they manage cannot be understated. As previously mentioned, it was identified that a large
majority of the surveyed providers indicated that they would be pursuing both continued
education as well as implementation of PGx testing in the management of their patients. The
surveyed providers identified that the most applicable use case for this testing would be the
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avoidance of adverse drug reaction events, which PGx testing results can be leveraged
advantageously towards this goal.
The limitations of this project are found within the severely limited number of providers
who responded to the invitation and met the requirements of finishing all the project’s materials
to be included for analysis. The results therefore cannot be generalized to any other context
outside of the one that has been studied within the confines of this project. There is also the
possibility for bias in those that did both respond to the invitation for inclusion and completed
the project’s materials, in that these providers may have been more open to both learning and
implementing PGx concepts when compared to the general pool of primary care providers. To
understand this better these results should be compared against those with similar aims that are
carried out in other primary care provider populations to determine if these results can be
validated.
Sustainability
The sustainability in accomplishing change of practice when it comes to implementation
of PGx testing is high. There is an ever-growing precedent based on many variables for the
implementation of PGx testing within the field of primary care. It has been shown in this project
that primary care providers will not implement testing that they do not understand, but if this
barrier of knowledge deficit can be addressed then it is likely that change in practice is
forthcoming. Priorities in the field of medicine are closely aligned with the principles of PGx
testing, which contributes heavily to the sustainability of practice change towards
implementation of this testing. PGx testing aims to primarily provide better outcomes for every
single patient who is evaluated and treated within the primary care context. PGx texting
secondarily aims to provide care that is precise, evidence-based, and cost-effective.
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Dissemination Plan
The plan for dissemination of the project’s results occurs through several mechanisms.
The first mechanism by which dissemination may happen is through the potential and likely
change in practice that will occur on the individual level in all the providers that took part in this
project. These providers indicated that as a result of participation in this project their
perspectives on PGx testing have changed, and that they will likely pursue further PGx testing
and implement PGx testing as part of their regular management. This change in practice for these
providers will likely cause colleagues or supervising physicians to take note of these changes and
evaluate the efficacy of PGx testing just as the surveyed providers have as a result of inclusion in
this project. The secondary mechanism for the dissemination of these results is for this project to
be published for those who are interested in the field of PGx testing, for those who wish to know
how this may affect the management of patients in the primary care setting, and finally for those
who are interested in pursuing research regarding PGx testing’s impact on clinical practice.
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Appendix A
Evidence Table
Name: Joshua Fleming
Clinical Question: How does a targeted educational intervention affect the reported level of understanding and perspectives for
providers in a primary care health system?
Article Title, Author,
etc. (Current APA
Format)

Example, A. (2015) Title etc.
per Current APA

Study Purpose

To identify the need for technology to
prevent falls

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

A convenience
sample of 44 nurses
in an acute care
hospital

Methods

Study Results

A non-experimental,
descriptive survey

Findings indicate that
fall rates decreased by
2% with the
introduction of
technology into the
care setting

Level of
Evidence (Use
Melnyk
Framework)

Level 6:
descriptive
design

Study
Limitations

Conducted in
only one
setting, small
sample size

Would Use as
Evidence to
Support a
Change? (Yes or
No) Provide
Rationale.

Does provide some
good foundational
information even
though the level is a
6.
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Article Title, Author,
etc. (Current APA
Format)

Relling, M.V., & Evans,
W.E. (2015).
Pharmacogenomics in the
clinic. Nature, 526(7573),
343

Study Purpose

To provide background information
regarding the growing field of
pharmacogenomic testing and its efficacy
in clinical practice.

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

Literature review of
related and relevant
literature regarding
this subject.
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Methods

Study Results

No details regarding
processes by which
literature was
obtained are
mentioned in the
article.

Authors conclude that
there is a growing
body of knowledge
regarding
pharmacogenomics
testing, which is
greatly impacted by
the advent of the
human genome project
and increased
understanding
regarding the subject
of genetics in general.
Discussed here is the
potential level of
impact that discoveries
regarding
pharmacogenes can
have on the change in
treatment methods and
patient outcomes.

Level of
Evidence (Use
Melnyk
Framework)

Level 6:
Descriptive
design

Study
Limitations

Would Use as
Evidence to
Support a
Change? (Yes or
No) Provide
Rationale.

The study falls
short in not
providing
specific
recommendatio
ns for further
work to be
done in order
to move the
field of study
forward.

Yes. This study
provides
significant
general insights
into the subject of
pharmacogenomi
cs testing as well
as the barriers to
further
implementation
of this in clinical
practice.
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Article Title, Author,
etc. (Current APA
Format)

Rosenman, M.B., Decker,
B., Levy, K.D., Holmes,
A.M., Pratt, V.M., & Eadon,
M.T. (2017). Lessons
learned when introducing
pharmacogenomic panel
testing into clinical practice.
Value in Health, 20(1), 5459.

Study Purpose

This study describes the challenges and
potential solutions to implementation
projects of pharmacogenomics testing
being provided.
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Sample
(Characteristics of
the Sample:
Demographics,
etc.)

Methods

Study Results

A diverse population
(patients who often
have multiple chronic
illnesses, in a large
urban safety-net
hospital and its
outpatient clinics).

The study was
conducted as a
descriptive case
study of the
implementation of a
pharmacogenomics
program with wide
scope (14 genes, 43
variants, and 27
medications).

The study identified
several areas of
challenges that were
developed through
observation and
evaluation of the
implementation
process in this care
environment that
included both extrinsic
factors, patientmediated factors, and
provider-mediated
factors.

Level of
Evidence (Use
Melnyk
Framework)

Level 6:
Descriptive
design

Study
Limitations

Would Use as
Evidence to
Support a
Change? (Yes or
No) Provide
Rationale.

The problem of
cost for testing
is addressed by
means of
correlation
with the rise of
other
interventions
that have been
promised as
revolutionary
in theory yet
complex and
inconclusive in
practice. This
may be helpful
in predicting
the complex
implementation
process of
pharmacogeno
mics testing in
primary care,
but this
relationship is
not proven to
be concrete or
predictive of
the future of
pharmacogeno
mics testing.

Yes. The information
gleaned through
experiencing multifaceted variables that
serve as potentially
significant barriers
against
implementation
efforts proves to pave
the road forward for
further investigation
and intervention to
address these issues
effectively.
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Article Title, Author,
etc. (Current APA
Format)

Study Purpose

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

Methods

Study Results

Just, K.S., Steffens, M.,
Swen, J.J., Patrinos, G.P.,
Guchelaar, H.J., & Stingl,
J.C. (2017). Medical
education in
pharmacogenomics—results
from a survey on
pharmacogenetic knowledge
in healthcare professionals
within the European
pharmacogenomics clinical
implementation project
Ubiquitous
Pharmacogenomics (UPGx). European Journal of
Clinical Pharmacology,
73(10), 1247-1252.

To evaluate the attitudes, experience
with, and education on pharmacogenomic
testing in medical providers who are
expected to be the leaders of this new
change towards the future where this
testing is part of regular evaluation and
management of patients.

The sample group
was comprised of 70
individuals that was a
combination of
physicians and
pharmacists.

The authors
developed a
questionnaire
including 29
questions. It was
spread out to
healthcare
professionals
working at the
future
implementation
sites (in Austria,
Greece, Italy,
Netherlands,
Slovenia, Spain and
Great Britain) of the
U-PGx project in
preparation of an
educational
programme. Aim of
the survey was to
analyse the current
educational
situation at the
implementation
sites.

The results showed
that even though a vast
majority of the
respondents (more
than 84%) showed that
pharmacogenomics
was relevant to their
current practice it was
still not prevalent as
more than 65% of
respondents had not
ordered or
recommended testing
in the last year.

Level of
Evidence (Use
Melnyk
Framework)

Level 6:
Descriptive
design

Study
Limitations

Would Use as
Evidence to
Support a
Change? (Yes or
No) Provide
Rationale.

The study
showcased a
significant
barrier to the
implementation
of
pharmacogeno
mics testing in
clinical
practice as
being a lack of
knowledge and
specific
education
regarding the
interpretation
of testing
results, but this
study fails to
propose any
meaningful
intervention
based on these
findings.

Yes. The evidence
presented in this
study is crucial to
understand as part of
further research into
the education that is
necessary for
physicians in existing
practice as well as the
potential for
integration of
changes to the
curriculum of
medical students who
are going to be the
most affected by
these potential
changes in the future.
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Article Title, Author,
etc. (Current APA
Format)

Study Purpose

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

Methods

Study Results

Plumpton, C. O., Roberts,
D., Pirmohamed, M., &
Hughes, D. A. (2016). A
systematic review of
economic evaluations of
pharmacogenetic testing for
prevention of adverse drug
reactions. PharmacoEconom
ics, 34(8), 771-793.

This study is aimed at the costeffectiveness evaluation of
pharmacogenomic testing through
systematic review of literature to prevent
adverse drug reactions in patients that are
about to be placed on medications that
can be heavily affected by genetic
factors.

47 of a total of 852
articles met inclusion
criteria for
independent review
of both abstract and
full text.

The systematic
review protocol was
registered with
PROSPERO, the
international
database of
prospectively
registered
systematic reviews
(identification
number
CRD42014013673),
conducted
according to the
Centre for Reviews
and Dissemination’s
guidance for
undertaking reviews
in healthcare.

There was evidence
supporting the cost
effectiveness of testing
for HLA-B*57:01
(prior to abacavir),
HLA-B*15:02 and
HLA-A*31:01 (prior
to carbamazepine),
HLA-B*58:01 (prior
to allopurinol) and
CYP2C19 (prior to
clopidogrel treatment).
Economic evidence
was inconclusive with
respect to TPMT
(prior to 6mercaptoputine,
azathioprine and
cisplatin therapy),
CYP2C9 and
VKORC1 (to inform
genotype-guided
dosing of coumarin
derivatives), MTHFR
(prior to methotrexate
treatment) and factor
V Leiden testing (prior
to oral contraception).
Testing for A1555G is
not cost effective
before prescribing
aminoglycosides.

Level of
Evidence (Use
Melnyk
Framework)

Level 1:
Systematic
Review

Study
Limitations

Would Use as
Evidence to
Support a
Change? (Yes or
No) Provide
Rationale.

While the
study’s results
were shown to
have
conclusive
findings
regarding the
costeffectiveness in
providing
pharmacogeno
mic testing in
for some
medications,
there are still
those that
require further
investigation
because of
inconclusive or
mixed results.

Yes. This systematic
review evaluates the
cost-effectiveness for
pharmacogenomics
based on reduction in
adverse drug side
effects. With the
financial implications
of
pharmacogenomics
testing it is necessary
to understand how
this testing will
provide economic
advantages to both
patients, insurance
providers, and health
systems overall
which support the
successful
implementation of
this testing in the
future.
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Berm, E. J. J., de Looff, M.,
Wilffert, B., Boersma, C.,
Annemans, L., Vegter, S., &
Postma, M. J. (2016).
Economic evaluations of
pharmacogenetic and
pharmacogenomic screening
tests: A systematic review.
second update of the
literature. PLoS One, 11(1)

To evaluate the literature on the
economic implications of
pharmacogenomics screening tests to
help determine if this testing is cost
effective.

80 articles were
found to meet
inclusion criteria of
the initial 733 articles
that were found
regarding the subject
matter.

A literature search
was performed in
PubMed and papers
published between
August 2010 and
September 2014,
investigating the
cost-effectiveness of
PGx screening tests,
were included.
Papers from 2000
until July 2010 were
included via two
previous systematic
reviews. Studies’
overall quality was
assessed with the
Quality of Health
Economic Studies
(QHES) instrument.

The literature review
found that testing was
mostly a cost-effective
or cost-saving
intervention across the
studies that were
accumulated and
evaluated.

Level 1:
Systematic
Review

Kirchheiner, J., Fuhr, U., &
Brockmöller, J. (2005).
Pharmacogenetics-based
therapeutic
recommendations -- ready
for clinical practice? Nature

The study discusses different variations
and factors that affect or inhibit the use
and application of pharmacogenomics
testing in real-world clinical
environments

The study is a
literature review that
does not have
definable search
terms or

The article does not
contain specific
parameters for the
methods by which
the evidence was

Based on the articles
reviewed by the
authors, it was found
that there are several
limitations to the field
of pharmacogenomics

Level 6:
Descriptive
design

It is difficult to
provide
conclusive and
concrete
economic
evaluations
that are
established as a
standard
because of
several
different
variables such
as lack of hard
clinical
evidence
regarding the
pharmacogeno
mics testing’s
utility in the
clinical setting,
variability in
compliance in
physicians who
are ordering
the testing and
not changing
management
based off of
recommendatio
ns, and the
variability in
price of
pharmacogeno
mics testing
between
different
geographical
environments.
The study
notes these
polymorphisms
being detected
in patients, but
fails to

Yes. This systematic
review contains a
robust foundation for
the validity of
pharmacogenomics
testing as part of
regular screening and
management from the
perspective of
economic
implications, which
is a large concern
surrounding this field
in the literature.

Yes. This review
describes several
different case studies
where there have
been, in some cases,
significant adverse
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Reviews. Drug
Discovery, 4(8), 639-647.

Study Purpose

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

inclusion/exclusion
criteria listed

Methods

compiled or
proposed
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Study Results

that limit its
implementation and
application in clinical
practice

Level of
Evidence (Use
Melnyk
Framework)

Study
Limitations

Would Use as
Evidence to
Support a
Change? (Yes or
No) Provide
Rationale.

substantiate
how these
findings will be
repeated in
large-scale
studies or the
implications to
clinical
practice based
on the results
of those
hypothetical
studies

effects that have been
noted in patients with
known
polymorphisms
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Article Title, Author,
etc. (Current APA
Format)

Study Purpose

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

Methods

Study Results

Wong, W. B., Carlson, J. J.,
Thariani, R., & Veenstra, D.
L. (2010). Cost effectiveness
of
pharmacogenomics. Pharma
coEconomics, 28(11), 10011013.

To provide a foundational understanding
regarding the economics of
pharmacogenomics testing through
systematic review of literature that
discusses these points

34 articles were
included in the
review of literature
from an original 54
articles that were
selected based off of
other reviews of
literature and new
evidence

A literature search
was performed
during October
2009 using the
following publically
available databases:
PubMed, UK
National Institute
for Health and
Clinical Excellence
(NICE).Tufts CEA
registry and
Canadian Agency
on Drugs and
Technology in
Health (CADTH).
We employed a
literature search
strategy similar to a
previous CEA of
PGx reviews, which
involved starting
with broad search
terms, then
narrowing down to
specific Medical
Subject Heading
(MeSH) terms,
followed by diseasespecific searches
and expert
recommendations.

The studies that were
surveyed and
evaluated found that
there were many
biogenetic markers
that had clinical
significance, but only
two that possessed
clinical significance as
well as clinical utility
based on the economic
benefits that these may
possess for the patient
populations that can be
served by them

Level of
Evidence (Use
Melnyk
Framework)

Level 1:
Systematic
Review

Study
Limitations

Would Use as
Evidence to
Support a
Change? (Yes or
No) Provide
Rationale.

There are
limitations in
the current
base of
evidence on
how the results
of the studies
that were
included in this
review have on
clinical
practice based
on insufficient
evidence and
inconclusive
results

Yes. There is
supporting evidence,
though not
conclusive, to
support the costeffectiveness of
pharmacogenomics
testing having a place
in regular clinical
practice
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Phillips, K.A., Veenstra,
D.L., Oren, E., Lee, J.K.,
Sadee, W. (2001). Potential
role of pharmacogenomics in
reducing adverse drug
reactions: a systematic
review. Journal of the
American Medical
Association, 286(14), 22702279.

Study Purpose

To evaluate the potential role of
pharmacogenomics in reducing the
incidence of adverse drug reactions
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Sample
(Characteristics of
the Sample:
Demographics,
etc.)

Methods

Study Results

Detailed inclusion
criteria were used to
select studies. 18 of
333 adverse drug
reaction studies and
22 of 61 variant allele
review articles were
included in the final
review

MEDLINE Englishlanguage only
searches for adverse
drug reaction
studies published
between January
1995 and June 2000
and review articles
of variant alleles of
drug-metabolizing
enzymes published
between January
1997 and August
2000.

Results suggest that
drug therapy based on
individuals' genetic
makeups may result in
a clinically important
reduction in adverse
outcomes

Level of
Evidence (Use
Melnyk
Framework)

Level 1:
Systematic
Review

Study
Limitations

Would Use as
Evidence to
Support a
Change? (Yes or
No) Provide
Rationale.

The
information
included here,
while being a
solid
foundation for
further study
and potential
implications to
clinical
practice, it is
old evidence in
a subject that is
constantly
evolving into
greater scopes
and practices

Yes. Even though the
evidence may be old
the information here
should be referenced
in continual work
towards further
research and greater
applications in
clinical practice
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Study Purpose

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

Methods

Adams, S. M., Anderson, K.
B., Coons, James C, Smith,
R. B., Meyer, S. M., Parker,
L. S., & Empey, Philip, E.
(2016). Advancing
pharmacogenomics
education in the core
PharmD curriculum through
student personal genomic
testing. American Journal of
Pharmaceutical
Education, 80(1), 1-11.

To evaluate the impact of personal
genetic testing on the educational benefits
for pharmD students learning these
concepts as part of curriculum

Study consisted 110
PharmD students and
10 faculty members

Study involved preand post-survey
tools to evaluate for
changes in
perception and level
of understanding
that was proposed to
be affected or
changed by the
implementation of
this new type of
curriculum
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Study Results

It was found that
students who
underwent genetic
testing were found to
have significant
advantages in
understanding and
manipulation of
curriculum materials
when compared with
students who did not
take part in the
intervention

Level of
Evidence (Use
Melnyk
Framework)

Level 3:
QuasiExperiment
al Design

Study
Limitations

Would Use as
Evidence to
Support a
Change? (Yes or
No) Provide
Rationale.

The study is
limited by its
poor discussion
surrounding
the areas of
difference in
outcomes that
were achieved
by the students
who were
participants in
the genetic
testing as
compared to
students who
did not take
part in this

Yes. The study
provides insight into
novel concepts
regarding the
education of future
clinicians who are
expected to have
robust understanding
regarding genetic
testing and
implications on
clinical practice to
achieve higher buy-in
from these
individuals and, inturn, provide better
outcomes for
adherence to testing
as well as better
understanding.
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Ferreri, S.P., Greco, A.J.,
Michaels, N.M., O’Connor,
S.K., Chater, R.W., Viera,
A.J., Faruki, H., McLeod,
H.L., & Roederer, M.W.
(2014). Implementation of a
pharmacogenomics in a
community pharmacy,
Journal of the American
Pharmacists Association,
54(2), 172-180.

Study Purpose

To determine the feasibility of
implementing a pharmacogenomics
service in a community pharmacy

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

18 patients taking
clopidogrel, a drug
metabolized by
CYP2C19.
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Methods

Study Results

A retrospective data
abstraction of
prescription fills
between the dates of
May 1, 2011, and
October 26, 2011,
yielded 53 patients
with at least one fill
of clopidogrel.
Since this was a
feasibility project,
any patient with a
prescription for
clopidogrel was
included. A final
sample of 18 were
determined based on
other
inclusion/exclusion
criteria

A pharmacogenomics
service can be an
extension of
medication therapy
management services
in a community
pharmacy. Prescribers
are receptive to having
community
pharmacists conduct
pharmacogenomics
testing, but
reimbursement is a
challenge.

Level of
Evidence (Use
Melnyk
Framework)

Level 4:
Correlation
al Design

Study
Limitations

Would Use as
Evidence to
Support a
Change? (Yes or
No) Provide
Rationale.

The study did
not adequately
explain why
the insurance
agencies in
these cases
were reluctant
towards
reimbursement
or how this
difficulty can
be overcome in
future studies
or work
towards
clinical
practice.

Yes. This study
demonstrates
practical application
of
pharmacogenomics
testing being carried
out on a drug with
known significant
side effects for
persons with genetic
abnormalities and
proposes how the
relationship with
pharmacists carrying
out this testing can
work in the care-team
environment with
suggestions made
towards the
prescribers based on
the results that are
examined in these
patients
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Article Title, Author,
etc. (Current APA
Format)

Study Purpose

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

Methods

Study Results

Benitwez, J., Jablonski,
M.R., Allen, J.D., & Winner,
J.G. (2015). The clinical
validity and utility of
combinatorial
pharmacogenomics:
Enhancing patient outcomes.
Applied and Translational
Genomics, 5(1), 47-49.

This study evaluates the differences
measured in clinical validity, utility, and
economic benefit to the patient between
single gene evaluations and
combinatorial pharmacogenomics panels
that are designed to evaluate multiple
genes in an individual that is receiving
psychiatric pharmacotherapies

The study evaluates
three studies done on
the clinical validity,
three studies on the
clinical utility, and an
undisclosed amount
of clinical research
on the economic
impact of
combinatorial
pharmacogenomics
testing panels for
patients receiving
psychiatric
pharmacotherapies

The methods by
which this evidence
is compiled or
evaluated is not
disclosed in the
contents of the
article

The authors concluded
based on the amassed
clinical research that
the use of
combinatorial
pharmacogenomics
testing panels showed
a significant efficacy
in all three defined
domains of interest,
thus showing
preference for this
type of testing for
better outcomes as
well as further
implications for the
field in evaluating
these results on a
larger scale

Level of
Evidence (Use
Melnyk
Framework)

Level 6:
Descriptive
Design

Study
Limitations

Would Use as
Evidence to
Support a
Change? (Yes or
No) Provide
Rationale.

The study’s
limitations
surround the
small amount
of evidence in
previous
studies that
support the
purported
conclusion, and
highlights the
need for further
research and
replication of
findings that
are listed here
for increased
basis on
change in
clinical
practice

Yes. The study
provides preliminary
evidence that suggest
promising benefits in
three variables of
pharmacogenomics
testing that are often
listed as barriers
towards greater
implementation and
effective change in
practice
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Brown, L.C., Lorenz, R.A.,
Li, J., & Dechairo, B.M.
(2017). Economic utility:
Combinatorial
pharmacogenomics and
medication cost savings for
mental health care in a
primary care setting. Clinical
Therapeutics, 39(3).

The primary objective of this study was
to determine potential cost savings of
combinatorial PGx testing over the
course of 1 year in patients with mental
illness treated by primary care providers
(PCPs) and psychiatrists who had
switched or added a new psychiatric
medication after patients failed to
respond to monotherapy.

Of the 2168 patients,
1662 were taking
eligible GeneSight
panel medications
365 days after the
combinatorial PGx
test date and were
included in this subanalysis.

This study was a
sub-analysis of a 1year, prospective
trial comparing
medication costs of
2168 patients
undergoing
GeneSight testing.
Pharmacy claims
were provided by a
pharmacy benefits
manager, comparing
medication costs 6
months before
combinatorial PGx
testing and followed
up for 1 year after
the testing. This
analysis compared
congruence and cost
savings per patient
based on the type
of health care
provider administeri
ng care.

PCPs congruent with
combinatorial PGx
testing provided the
most medication cost
savings for payers and
patients at $3988 per
member per year

Level 4:
Correlation
al Design

Romagnoli, K.M., Boyce,
R.D., Empey, P.E., Adams,
S., & Hochheiser, H. (2016).
Bringing clinical

The authors of the article sought to
understand the pharmacogenomics
information needs and resource
requirements of pharmacists as these are

The study included
14 pharmacists
located in 6 different
clinical environments

The authors
conducted
qualitative inquiries
and used the results

Responses suggest that
pharmacists anticipate
an imminently
growing role for

Level 6:
Descriptive
Design

The study
failed to
explain in
detail the
potential for
lack of
congruence in
pharmacogeno
mics testing
between PCPs
and
psychiatrists or
explicitly
explain points
of benefit for
PCPs being the
primary source
of
pharmacogeno
mics testing as
it was found
that there was
greater cost
savings for the
patients
because the
PCP was able
to not only
follow the
psychiatric
recommendatio
n results from
the testing but
also the nonpsychiatric
recommendatio
ns that the
testing brought
as part of the
combinatorial
panel
The study does
not provide
explicit
statistical data

Yes. The study
supports the
economic advantage
in providing
pharmacogenomics
testing with an
emphasis that this
testing should take
place in the PCP
setting to provide the
best economic impact
for the patients
seeking care

Yes. This study
shows the
perspectives of
several pharmacists
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pharmacogenomics
information to pharmacists:
A qualitative study of
information needs and
resource requirements,
International Journal of
Medical Informatics, 86, 5461.

Study Purpose

key participants in the decision-making
regarding pharmacotherapies in the
clinical setting

Sample
(Characteristics of
the Sample:
Demographics,
etc.)
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Methods

Study Results

of those inquiries to
develop a model of
pharmacists’
pharmacogenomics
information needs
and resource
requirements.

pharmacogenomics in
their practice.
Participants value
information from trustworthy resources like
FDA product labels,
but found that this
information was
difficult to accurately
and efficiently
approach

Level of
Evidence (Use
Melnyk
Framework)

Study
Limitations

Would Use as
Evidence to
Support a
Change? (Yes or
No) Provide
Rationale.

or evidence
that notes the
need for
increased
knowledge and
inclusion in
pharmacogeno
mics testing
beyond stating
that this field is
likely to need
the clinical
knowledge of
pharmacists for
better patient
outcomes

on the subject of
pharmacogenomics
and the need for
increased knowledge
and prevalence of
succinct and useful
clinical resources for
the utilization by
providers to better
provide meaningful
clinical decisions
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St Stauver, J.L., Bielinski,
S.J., Olson, J.E., Bell, E.J.,
McGree, M.E., Jacobson,
D.J., McCormick, J.B.,
Caraballo, P.J., Takahashi,
P.Y., Roger, V.L. & Vitek,
C.R. (2016). Integrating
pharmacogenomics into
clinical practice: Promise vs
reality, American Journal of
Medicine, 129(10), 10931099.

Study Purpose

To evaluate PCPs’ response to clinical
support systems that are aimed towards
providing better patient outcomes by
notifying the provider that a change is
recommended based on the patient’s
pharmacogenomics profile
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Sample
(Characteristics of
the Sample:
Demographics,
etc.)

Methods

Study Results

159 primary care
physicians in the
Mayo Clinic
network. Of this
original sample there
were only 90
respondants

Mayo Clinic
primary care
practice were sent email surveys to
understand their
perspectives on the
implementation and
use of
pharmacogenomic
testing in their
clinical practice.
Surveys assessed
how the clinicians
felt about
pharmacogenomics
and whether they
thought electronic
pharmacogenomics
clinical decision
support alerts were
useful.

Our results indicate
that clinicians are not
comfortable with the
integration of
pharmacogenomic
data into their clinical
practice. Because most
patients expect that
their
pharmacogenomic
data will help guide
their care decisions,
further efforts to
educate clinicians
about the utility of
pharmacogenomic
data for clinical
practice, and efforts to
refine PGx-CDS alerts
to make them useful
and user-friendly, may
close the gap between
the clinician's
approach and patient
expectations

Level of
Evidence (Use
Melnyk
Framework)

Level 4:
Correlation
al Design

Study
Limitations

Would Use as
Evidence to
Support a
Change? (Yes or
No) Provide
Rationale.

The limited
response rate
of 57% limits
the efficacy of
the data that is
pulled from
this specific
population and
does not
account for
individual
physicians who
are outliers
with either
negative or
positive bias
based on
personal
experience
with the
clinical
decision
support tools

Yes. This study
features potentially
helpful insights into
better integration of
pharmacogenomics
testing clinical
decision support
systems in future care
settings that reflects
positive physician
interactions and
better outcomes with
adherence to change
in practice based on
recommendations
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Article Title, Author,
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Study Purpose

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

Methods

Study Results

Olson, J. E., Rohrer Vitek,
C. R., Bell, E. J., Mcgree, M.
E., Jacobson, D. J., St
Sauver, J. L., Bielinski, S. J.
(2017). Participant-perceived
understanding and
perspectives on
pharmacogenomics: The
mayo clinic RIGHT protocol
(right drug, right dose, right
time). Genetics in
Medicine, 19(7), 819-825.

The purpose of this study was to identify
variables included in educational
resources that are provided to patients
undergoing pharmacogenomics testing
that predict understanding as well as how
to further refine these materials based on
responses from those surveyed

A total of 1010
patients were chosen
based off of inclusion
and exclusion criteria
and of these patients
there were 869
respondants

The participants
were mailed their
individual
pharmacogenomics
test results along
with educational
materials and a
survey to complete
regarding their
understanding of the
presented materials
and potential for
this information to
improve medication
adherence

Even with increased
efforts paid towards
simplifying patient
education regarding
the results of
pharmacogenomics
testing it was found
that more than a third
of the surveyed
patients did not
understand the results

Appendix B

Level of
Evidence (Use
Melnyk
Framework)

Level 4:
Correlation
al Design

Study
Limitations

Would Use as
Evidence to
Support a
Change? (Yes or
No) Provide
Rationale.

The limitations
of this study
include the
potential for
these findings
to be
generalized
given specific
characteristic
of the surveyed
population
such as patients
who have a
higher level of
education
when
compared to
other samples
or a higher
likelihood in
response rates
because of bias
factors that
may be specific
to this
population

Yes. This study
highlights the
necessity of
providing patients
with the information
that they need in a
format that is not
confusing or using
terms that are
difficult for lay
people to understand.
This paves the way
for further refinement
of educational
materials which can
have significantly
positive impact on
the clinical benefits
of
pharmacogenomics
testing in patients
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Appendix D
This project took place outside of any formal organizational structure, which excludes this requirement of documented
organizational approval. This decision was corroborated with the researcher’s chair and Liberty University IRB personnel. Both of
these entities agreed that given the low risk status of this project’s aims that forgoing organizational approval for surveyed providers
was unnecessary.
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Appendix E

Pharmacogenomics Pre-survey Questions
1. What is your current level of knowledge on pharmacogenomics testing?
a. Never heard of it
b. Very little experience (Heard of it mentioned)
c. Limited understanding (Received any amount of formal training)
d. Solidified understanding (Feeling confident in simple concepts surrounding testing)
e. Advanced understanding (Received extensive education on concepts of testing)
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2. How often is pharmacogenomics testing part of your management currently?
a. Never
b. Sometimes (Less than 10 cases in a year)
c. Often (Less than 50 cases in a year)
d. Frequently (More than 50 cases in a year)
e. Every day
3. In your current practice, what is drug dosing primarily based on? (Select all that apply)
a. Renal function
b. Hepatic function
c. Age
d. Weight
e. Sex
f. Comorbid conditions
g. Clinical guidelines
h. Personal preference and familiarity
i. Biomarkers from pharmacogenomics testing
4. How clinically significant do you believe pharmacogenomics testing results are to patient outcomes?
a. No significance at all
b. Very little significance
c. Neutral
d. Somewhat significant
e. Very significant
5. Do you see the cost of testing as a prohibitive factor in implementing pharmacogenomics testing?
a. In all cases
b. In most cases
c. Neutral
d. In some cases
e. In no cases
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6. What is the main barrier for the implementation of pharmacogenomics testing in your current management of patients? (Select
all that apply)
a. Unfamiliarity with testing
b. Cost of testing
c. Lack of evidence for clinical use
d. Lack of impact on clinical practice
e. Clinical responsibility for testing results
7. What do you believe is the best application of pharmacogenomics testing in your current practice?
a. Preventative management
b. Polypharmacy concerns
c. Ineffectiveness of conventional therapies
d. Complex patient presentation and needs
e. No application at all
f. As part of regular management
8. How comfortable are you with interpreting pharmacogenomics testing results based on your current level of knowledge?
a. Completely uncomfortable
b. Somewhat uncomfortable
c. Neutral
d. Comfortable
e. Very comfortable
9. How important do you believe it is to include pharmacogenomics education in medical education curriculum?
a. Not important at all
b. Not very important
c. Neutral
d. Somewhat important
e. Very important
10. What formats do you believe are important for increased knowledge surrounding pharmacogenomics testing?
a. Conferences
b. Continuing education courses
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c. College
d. Graduate school (Medical school, PharmD school, PA school, NP school)
e. Internet-based education modules
11. What is your age?
a. < 25 years old
b. 25-34 years old
c. 35-45 years old
d. 45-55 years old
e. > 55 years old
12. What is your discipline?
a. Medical Doctor
b. Physician Assistant
c. Nurse Practitioner
d. Doctor of Osteopathic Medicine
e. Pharmacist
13. How many years of experience do you have in your current role?
a. 1-3 years of experience
b. 4-6 years of experience
c. 7-10 years of experience
d. 11-15 years of experience
e. 16-21 years of experience
f. 22-30 years of experience
g. > 30 years of experience
14. What is your gender?
a. Male
b. Female
15. How interested are you to receive education regarding pharmacogenomics testing?
a. Not interested at all
b. Not very interested
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c. Neutral
d. Interested
e. Very interested
Pharmacogenomics Post-survey Questions
1. How likely are you to pursue including pharmacogenomics testing in your clinical management of patients as a result of the
information provided in the educational intervention?
a. No likelihood
b. Not likely
c. Neutral
d. Somewhat likely
e. Very likely
2. What factors are still present that stand as barriers to implementation of testing? (Select all that apply)
a. Lack of foreseeable clinical impact
b. Cost of testing
c. Insufficient knowledge base
d. Clinical responsibility for testing
e. Not knowing when and who to test
3. How likely are you to pursue further pharmacogenomics education as a result of your participation in this project?
a. No likelihood
b. Not likely
c. Neutral
d. Somewhat likely
e. Very likely
4. The educational intervention in this project thoroughly addressed the barriers to implementation of pharmacogenomics testing.
a. Completely disagree
b. Somewhat disagree
c. Neutral
d. Somewhat agree
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e. Completely agree
Based on the project’s educational intervention, pharmacogenomics testing has clinical significance in the management of
primary care patients.
a. Completely disagree
b. Somewhat disagree
c. Neutral
d. Somewhat agree
e. Completely agree
Based on the project’s educational intervention, pharmacogenomics testing is financially viable in the management of primary
care patients.
a. Completely disagree
b. Somewhat disagree
c. Neutral
d. Somewhat agree
e. Completely agree
Based on the project’s educational intervention, pharmacogenomics concepts should be included in the preparatory curriculum
of those entering the medical field or offered as continuing education opportunities for the field of primary care.
a. Completely disagree
b. Somewhat disagree
c. Neutral
d. Somewhat agree
e. Completely agree
Based on the project’s educational intervention, pharmacogenomics testing is most appropriately accomplished for patients
within the primary care setting.
a. Completely disagree
b. Somewhat disagree
c. Neutral
d. Somewhat agree
e. Completely agree
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9. Based on the project’s educational intervention, pharmacogenomics testing implementation can greatly reduce adverse drug
reaction events.
a. Completely disagree
b. Somewhat disagree
c. Neutral
d. Somewhat agree
e. Completely agree
10. Based on the project’s educational intervention, pharmacogenomics testing should be considered for (Select all that apply):
a. No primary care patients
b. In cases where adverse drug reactions are more likely
c. In cases where polypharmacy is a concern
d. In patients where normal therapies are noted to be ineffective
e. In all primary care patients
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Appendix F
CONSENT FORM
Pharmacogenomics Testing in Primary Care: Barriers to Implementation
Joshua Fleming
Liberty University
School of Nursing

You are invited to be in a research study on how the current perspectives and level of understanding pertaining to the use of
pharmacogenomics testing in primary care settings are affected by targeted educational intervention. You were selected as a possible
participant because of the setting in which you work, the capability that you possess in potentially ordering pharmacogenomics testing,
specific perspectives and level of understanding that you may possess as it relates to the subject of pharmacogenomics in the primary
care setting, and availability for participation in educational intervention and post-surveying. You were also selected based on your
role in the primary care setting as either a physician, nurse practitioner, or physician assistant. Please read this form and ask any
questions you may have before agreeing to be in the study.

Joshua Fleming, a doctoral candidate in the School of Nursing at Liberty University, is conducting this study.

Background Information: The purpose of this study is aimed towards understanding the level of understanding and perspectives of
primary care providers, which include physicians, nurse practitioners, and physician assistants, on the subject of pharmacogenomics
testing. Specifically, the outcome being measured through this study is the level of impact that a targeted educational intervention has
on the level of understanding and perspectives of primary care providers. This will be evaluated through establishing baseline results
through pre-surveying and comparing this to the results that are evaluated through post-surveying after the targeted educational
intervention regarding pharmacogenomics is delivered.

Procedures: If you agree to be in this study, I would ask you to do the following things:
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1. Provide an accurate and unbiased baseline regarding current level of understanding and perspectives of pharmacogenomics in
the primary care setting. This will be established through the answering of questions in the pre-survey that will be delivered
electronically to your organizational email. It is asked that you answer all survey questions completely within two weeks of
initial dispersal.
2. Be willing to receive targeted educational intervention on the subject of pharmacogenomics testing that will be developed to
address barriers that have been noted in the literature as well as those that are identified to be prevalent among respondents,
based on pre-surveying results.
3. Provide an accurate and unbiased report regarding post-education level of understanding and perspectives of
pharmacogenomics testing in the primary care setting. This will be established through the answering of questions in the postsurvey that will be delivered electronically to your organizational email. It is asked that you answer all survey questions
completely within four weeks of initial dispersal of post-survey, which will coincide with dispersal of targeted educational
intervention.

Risks: The risks involved in this study are minimal, which means they are equal to the risks you would encounter in everyday life.

Benefits: The direct benefits participants should expect to receive from taking part in this study are gains in knowledge base regarding
the potential application of pharmacogenomics testing in the primary care setting, which contains many potential benefits for both
patients receiving care as well as providers who are managing these patients’ care. Benefits to society include the possible increasing
acceptance of pharmacogenomics testing in the primary care setting, and subsequent possible prevalence of this testing in regular care
and management, which stand to benefit patients seeking care in the primary care setting through affecting many different patient
outcomes positively.

Compensation: Participants will not be compensated for participating in this study.

Confidentiality: The records of this study will be kept private. In any sort of report I might publish, I will not include any information
that will make it possible to identify a subject. Research records will be stored securely, and only the researcher will have access to the
records. Data will be stored on a password locked computer and may be used in future presentations. After three years, all electronic
records will be deleted.
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Voluntary Nature of the Study: Participation in this study is voluntary. Your decision whether or not to participate will not affect
your current or future relations with Liberty University. If you decide to participate, you are free to not answer any question or
withdraw at any time.

How to Withdraw from the Study: If you choose to withdraw from the study, please inform the researcher that you wish to
discontinue your participation prior to submitting your study materials. Your responses will not be recorded or included in the study.

Contacts and Questions: The researcher conducting this study is Joshua Fleming. You may ask any questions you have now. If you
have questions later, you are encouraged to contact him at (919)-810-5427 / jmfleming2@liberty.edu. You may also contact the
researcher’s faculty chair, Ken Thompson, at kthompson55@liberty.edu.

If you have any questions or concerns regarding this study and would like to talk to someone other than the researcher[s], you are
encouraged to contact the Institutional Review Board, 1971 University Blvd., Green Hall Ste. 2845, Lynchburg, VA 24515 or email
at irb@liberty.edu.

Please notify the researcher if you would like a copy of this information for your records.
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Statement of Consent: I have read and understood the above information. I have asked questions and have received answers. I
consent to participate in the study.

______________________________________________________________________________
Signature of Participant

Date

______________________________________________________________________________
Signature of Investigator
(Liberty University, 2019)

Date
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